Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2021-11-04 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a Current Report of a Foreign Private Issuer filed with the SEC. It contains a press release about the authorization of clinical trial expansion by a regulatory agency, but does not include detailed financial statements or comprehensive financial data. The document length is short (2134 characters), and it primarily serves as a regulatory announcement rather than a full report. According to the rules, Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit into other specific categories like Annual Report or Interim Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-11-04 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 100% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a press release about a patent allowance notice issued by the Israeli Patent Office. The document is short (2137 characters) and primarily serves to furnish a press release as an exhibit. There are no financial statements, detailed financial data, or comprehensive reports included. The document is an announcement filing rather than a full report. According to the rules, such filings that do not contain substantive financial data and serve as regulatory announcements or press release filings fall under Regulatory Filings (RNS).
2021-10-05 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a press release announcement about the publication of clinical data, but does not include detailed financial statements or substantive financial data. The document length is 2165 characters, which is relatively short and primarily serves as a notification rather than a full report. According to the rules, such filings that announce or furnish press releases or other information without detailed financial data are classified as Regulatory Filings (RNS).
2021-10-04 English
REPORT OF FOREIGN PRIVATE ISSUER
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Enlivex Therapeutics Ltd., with the SEC. It announces the date and details of the company's 2021 Annual and Extraordinary General Meeting of Shareholders, including the availability of the proxy statement and proxy card as exhibits. The document does not contain the actual proxy materials but references them as attached exhibits. The content is primarily an announcement related to the AGM and proxy solicitation materials, not the AGM materials themselves or the voting results. Given the nature of the document as a Form 6-K reporting the proxy statement and proxy card, it fits best under Proxy Solicitation & Information Statement (PSI). The document length is short and it is an announcement of proxy materials rather than the full materials themselves, so it is not AGM Information (AGM-R).
2021-09-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a press release announcement about the initiation of dosing in a Phase IIb clinical trial. The document is short (2188 characters) and primarily serves to furnish a press release as Exhibit 99.1. There are no financial statements or detailed financial data present. The document is an announcement of information rather than a full report. According to the rules, such filings are classified as Regulatory Filings (RNS) because they do not fit into other specific categories and are not full financial reports or detailed presentations.
2021-09-22 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a press release about the initiation of a clinical trial authorized by the Israeli Ministry of Health. The document is short (2349 characters) and primarily serves to furnish a press release as Exhibit 99.1. There are no financial statements or detailed financial data included. The document is an announcement of information rather than a full report. According to the classification rules, such filings are best categorized as Regulatory Filings (RNS) because they do not fit into other specific categories and are not full financial reports or detailed presentations.
2021-08-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.